Manus, the proven bioalternatives scale-up platform, will welcome Congressman Buddy Carter (GA-01) to its Augusta BioFacility on Friday, October 24. Rep. Carter recently launched the American-Made Medicines Caucus, a group focused on promoting policies to onshore and friendshore pharmaceutical manufacturing, strengthen economic and national security interests, and reduce America’s reliance on adversarial countries for essential medications. The visit will highlight Manus’ partnership with the U.S. Department of Health and Human Services’ (HHS) Defense Production Act (DPA) Title III Program, under the Administration for Strategic Preparedness and Response (ASPR), to build domestic pharmaceutical manufacturing for critical medicines while driving job creation and investment in Georgia.

‍

Manus specializes in advanced biomanufacturing of complex natural products and essential medicines, pioneering the field of bioalternatives. Through its proprietary technology platform and U.S.-based scale-up and manufacturing capabilities, Manus is reducing dependency on unstable supply chains and building a resilient domestic workforce.

‍

“Manus is pioneering the future of bioalternatives and biomanufacturing, strengthening America’s supply chains and creating high-quality jobs here in Georgia,” says Ajikumar “Aji” Parayil, Founder and CEO of Manus. “We are proud to partner with ASPR to onshore production, expand manufacturing in Augusta, and keep the U.S. at the forefront of innovation and advanced manufacturing.”

‍

“This is about bolstering national, economic, and public health security by reducing reliance on foreign countries. By revitalizing domestic manufacturing capacity in Augusta and enabling the production of key starting materials for critical drugs, Manus is not only helping to secure America's health independence but also bringing new jobs and economic prosperity to Georgia,” notes Rep. Carter.

‍

Building the bioeconomy in rural America

Georgia now offers one of the most tangible examples of the bioeconomy in action. After the closure of NutraSweet’s massive Augusta facility in 2015, Manus acquired the site and the NutraSweet Company in 2018, recognizing the value of its manufacturing infrastructure. The facility now stands as one of the largest biomanufacturing facilities in the United States, repurposed to produce critical bioalternatives, including market-leading BioSweeteners and high-performance BioIngredients such as sustainable, supply-resilient citrus oil replacements.

‍

Many former NutraSweet employees – displaced when operations were shuttered due to foreign competition – have been rehired, now working alongside scientists and engineers from leading institutions to build the bioeconomy of the future. Today, the Augusta BioFacility supports more than 100 high-quality jobs in rural Georgia while delivering sustainable bioalternative products at scale. The facility now stands as one of the largest biomanufacturing facilities in the United States, repurposed to produce critical bioalternatives, including market-leading BioSweeteners and high-performance BioIngredients such as sustainable, supply-resilient citrus oil replacements.

‍

Many former NutraSweet employees – displaced when operations were shuttered due to foreign competition – have been rehired, now working alongside scientists and engineers from leading institutions to build the bioeconomy of the future. Today, the Augusta BioFacility supports more than 100 high-quality jobs in rural Georgia while delivering sustainable bioalternative products at scale.

‍

‍